{
    "clinical_study": {
        "@rank": "161566", 
        "arm_group": [
            {
                "arm_group_label": "ZGN-440 sterile diluent", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks."
            }, 
            {
                "arm_group_label": "ZGN-440 for injectable suspension", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of\n      beloranib in obese subjects with hypothalamic injury."
        }, 
        "brief_title": "An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Obesity", 
            "Over-weight", 
            "Hypothalamic Injury", 
            "Craniopharyngioma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Craniopharyngioma", 
                "Adamantinoma", 
                "Obesity", 
                "Overweight", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Obesity as a consequence of acquired anatomical hypothalamic damage as evidenced by\n             BMI \u226530 and \u226460 kg/m2\n\n          -  Greater than 6 months post-treatment, including chemotherapy, surgery or radiation\n             with resulting injury to the hypothalamus and/or the pituitary\n\n          -  Stable body weight for at least 3 months\n\n          -  Type 2 diabetes mellitus is allowed\n\n        Exclusion Criteria:\n\n          -  Males taking gonadotropin replacement therapy (LH/FSH)\n\n          -  Subjects who are planning any fertility treatment within 6 months of study\n             participation\n\n          -  Use of weight loss agents, including herbal medications, in the past 3 months\n\n          -  Current or anticipated chronic use of narcotics or opiates\n\n          -  History of severe psychiatric disorders\n\n          -  Type 1 diabetes mellitus\n\n          -  Metabolic disorders or genetic disorders linked to obesity\n\n          -  History of any bariatric surgery\n\n          -  Participation in any clinical study with an investigational drug or device within the\n             3 months prior to enrollment in this study\n\n          -  Blood loss or donation >500 mL within the past 3 months\n\n          -  Females who are pregnant, nursing, intend to become pregnant during the study or any\n             males who plan to father/conceive a child within 6 months after completion of study\n             participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063295", 
            "org_study_id": "ZAF-221"
        }, 
        "intervention": [
            {
                "arm_group_label": "ZGN-440 sterile diluent", 
                "description": "ZGN-440 sterile diluent/placebo", 
                "intervention_name": "ZGN-440 sterile diluent", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ZGN-440 sterile diluent", 
                    "Placebo"
                ]
            }, 
            {
                "arm_group_label": "ZGN-440 for injectable suspension", 
                "intervention_name": "ZGN-440 for injectable suspension", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ZGN-440 for injectable suspension", 
                    "ZGN-440", 
                    "Beloranib"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Beloranib", 
            "ZGN-440", 
            "ZGN-440 for injectable suspension", 
            "ZGN-433"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "christine.benoit@childrensmn.org", 
                    "last_name": "Christine Benoit", 
                    "phone": "651-220-6254"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Paul", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55102"
                    }, 
                    "name": "Children's Hospitals and Clinics of Minnesota"
                }, 
                "investigator": {
                    "last_name": "Jennifer Abuzzahab, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "margo.black@vanderbilt.edu", 
                    "last_name": "Margo Black", 
                    "phone": "615-936-8638"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ashley Shoemaker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nick.fuller@sydney.edu.au", 
                    "last_name": "Nick Fuller", 
                    "phone": "+61 2 9036 3468"
                }, 
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2006"
                    }, 
                    "name": "The Boden Institute"
                }, 
                "investigator": {
                    "last_name": "Tania Markovic, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "purcellk@unimelb.edu.au", 
                    "last_name": "Katrina Purcell", 
                    "phone": "+61 3 94964025"
                }, 
                "facility": {
                    "address": {
                        "city": "Heidelberg Heights", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3081"
                    }, 
                    "name": "Austin Health, Metabolic Disorders Centre"
                }, 
                "investigator": {
                    "last_name": "Joseph Proietto, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Therapeutic Goods Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in body weight from baseline to the end of the randomized dosing period.", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063295"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in lipid profile (cholesterol, LDL, HDL, triglycerides) from baseline to the end of the randomized dosing period", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Change in hs-CRP from baseline to the end of the randomized dosing period.", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Change in hunger from baseline to the end of the randomized dosing period.", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Change in quality of life from baseline to the end of the randomized dosing period.", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Zafgen, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zafgen, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}